LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article ; Online: Effect of neonatal seizure burden and etiology on the long-term outcome: data from a randomized, controlled trial.

Trowbridge, Sara K / Condie, Lois O / Landers, Jessica R / Bergin, Ann M / Grant, Patricia E / Krishnamoorthy, Kalpathy / Rofeberg, Valerie / Wypij, David / Staley, Kevin J / Soul, Janet S

Annals of the Child Neurology Society

2023 Volume 1, Issue 1, Page(s) 53–65

Abstract: Background: Neonatal seizures are common, but the impact of neonatal seizures on long-term neurologic outcome remains unclear. We addressed this question by analyzing data from an early-phase controlled trial of bumetanide to treat neonatal seizures.: ...

Abstract	Background: Neonatal seizures are common, but the impact of neonatal seizures on long-term neurologic outcome remains unclear. We addressed this question by analyzing data from an early-phase controlled trial of bumetanide to treat neonatal seizures. Methods: Neonatal seizure burden was calculated from continuous video-EEG data. Neurologic outcome was determined by standardized developmental tests and post-neonatal seizure recurrence. Results: Of 111 enrolled neonates, 43 were randomized to treatment or control groups. There were no differences in neurologic outcome between treatment and control groups. A subgroup analysis was performed for 84 neonates with acute perinatal brain injury (57 HIE, 18 stroke, 9 ICH), most of whom (70%) had neonatal seizures. There was a significant negative correlation between seizure burden and developmental scores (p<0.01). Associations between seizure burden and developmental scores were stronger in HIE and stroke groups compared with ICH (p<0.05). Conclusion: Bumetanide showed no long-term beneficial or adverse effects, as expected based on treatment duration versus duration of neonatal seizures. For neonates with perinatal brain injury, higher neonatal seizure burden correlated significantly with worse developmental outcome, particularly for ischemic versus hemorrhagic brain injury. These data highlight the need for further investigation of the long-term effects of both neonatal seizure severity and etiology.
Language	English
Publishing date	2023-01-27
Publishing country	United States
Document type	Journal Article
ISSN	2831-3267
ISSN (online)	2831-3267
DOI	10.1002/cns3.8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Bromodomain Proteins Epigenetically Regulate the Mitotically Associated lncRNA MANCR in Triple Negative Breast Cancer Cells.

Tracy, Kirsten M / Prior, Shannon / Trowbridge, Willem T / Boyd, Joseph R / Ghule, Prachi N / Frietze, Seth / Stein, Janet L / Stein, Gary S / Lian, Jane B

Critical reviews in eukaryotic gene expression

2023 Volume 34, Issue 2, Page(s) 61–71

Abstract: Long non-coding RNA (lncRNA)-mediated control of gene expression contributes to regulation of biological processes that include proliferation and phenotype, as well as compromised expression of genes that are functionally linked to cancer initiation and ... ...

Abstract	Long non-coding RNA (lncRNA)-mediated control of gene expression contributes to regulation of biological processes that include proliferation and phenotype, as well as compromised expression of genes that are functionally linked to cancer initiation and tumor progression. lncRNAs have emerged as novel targets and biomarkers in breast cancer. We have shown that mitotically associated lncRNA MANCR is expressed in triple-negative breast cancer (TNBC) cells and that it serves a critical role in promoting genome stability and survival in aggressive breast cancer cells. Using an siRNA strategy, we selectively depleted BRD2, BRD3, and BRD4, singly and in combination, to establish which bromodomain proteins regulate MANCR expression in TNBC cells. Our findings were confirmed by using in situ hybridization combined with immunofluorescence analysis that revealed BRD4, either alone or with BRD2 and BRD3, can support MANCR regulation of TNBC cells. Here we provide evidence for MANCR-responsive epigenetic control of super enhancers by histone modifications that are required for gene transcription to support cell survival and expression of the epithelial tumor phenotype in triple negative breast cancer cells.
MeSH term(s)	Humans ; Triple Negative Breast Neoplasms/metabolism ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Cell Survival ; Gene Expression Regulation, Neoplastic ; Cell Line, Tumor ; Cell Proliferation/genetics ; Bromodomain Containing Proteins ; Cell Cycle Proteins/genetics
Chemical Substances	RNA, Long Noncoding ; Nuclear Proteins ; Transcription Factors ; BRD4 protein, human ; Bromodomain Containing Proteins ; Cell Cycle Proteins
Language	English
Publishing date	2023-12-11
Publishing country	United States
Document type	Journal Article
ZDB-ID	1071345-1
ISSN	1045-4403
ISSN	1045-4403
DOI	10.1615/CritRevEukaryotGeneExpr.2023050109
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3226: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Dermatan sulfate: new functions from an old glycosaminoglycan.

Trowbridge, Janet M / Gallo, Richard L

Glycobiology

2002 Volume 12, Issue 9, Page(s) 117R–25R

Abstract: Glycosaminoglycans constitute a considerable fraction of the glycoconjugates found on cellular membranes and in the extracellular matrix of virtually all mammalian tissues. Their ability to bind and alter protein-protein interactions or enzymatic ... ...

Abstract	Glycosaminoglycans constitute a considerable fraction of the glycoconjugates found on cellular membranes and in the extracellular matrix of virtually all mammalian tissues. Their ability to bind and alter protein-protein interactions or enzymatic activity has identified them as important determinants of cellular responsiveness in development, homeostasis, and disease. Although heparan sulfate tends to be emphasized as the most biologically active glycosaminoglycan, dermatan sulfate is a particularly attractive subject for further study because it is expressed in many mammalian tissues and it is the predominant glycan present in skin. Dermatan and dermatan sulfate proteoglycans have also been implicated in cardiovascular disease, tumorigenesis, infection, wound repair, and fibrosis. Growing evidence suggests that this glycosaminoglycan, like the better studied heparin and heparan sulfate, is an important cofactor in a variety of cell behaviors.
MeSH term(s)	Blood Coagulation/physiology ; Carbohydrate Sequence ; Dermatan Sulfate/chemistry ; Dermatan Sulfate/metabolism ; Dermatan Sulfate/physiology ; Extracellular Matrix/metabolism ; Growth Substances/metabolism ; Humans ; Molecular Sequence Data ; Molecular Structure ; Wound Healing
Chemical Substances	Growth Substances ; Dermatan Sulfate (24967-94-0)
Language	English
Publishing date	2002-09
Publishing country	England
Document type	Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
ZDB-ID	1067689-2
ISSN	1460-2423 ; 0959-6658
ISSN (online)	1460-2423
ISSN	0959-6658
DOI	10.1093/glycob/cwf066
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3150: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

The Lancet. Oncology

2021 Volume 22, Issue 6, Page(s) 872–882

Abstract: Background: Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody-drug ... ...

Abstract	Background: Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody-drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma. We aimed to evaluate the efficacy and safety of enfortumab vedotin in the post-immunotherapy setting in cisplatin-ineligible patients. Methods: EV-201 is a multicentre, single-arm, phase 2 study of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors. Cohort 2 included adults (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status score of 2 or less who were considered ineligible for cisplatin at enrolment and who had not received platinum-containing chemotherapy in the locally advanced or metastatic setting. Enfortumab vedotin was given intravenously at a dose of 1·25 mg/kg on days 1, 8, and 15 of every 28-day cycle. The primary endpoint was confirmed objective response rate per Response Evaluation Criteria in Solid Tumours version 1.1 assessed by blinded independent central review. Efficacy and safety were analysed in all patients who received at least one dose of enfortumab vedotin. EV-201 is an ongoing study and the primary analysis is complete. This study is registered with Clinicaltrials.gov, NCT03219333. Findings: Between Oct 8, 2017, and Feb 11, 2020, 91 patients were enrolled at 40 sites globally, of whom 89 received treatment. Median follow-up was 13·4 months (IQR 11·3-18·9). At data cutoff (Sept 8, 2020), the confirmed objective response rate was 52% (46 of 89 patients; 95% CI 41-62), with 18 (20%) of 89 patients achieving a complete response and 28 (31%) achieving a partial response. 49 (55%) of 89 patients had grade 3 or worse treatment-related adverse events. The most common grade 3 or 4 treatment-related adverse events were neutropenia (eight [9%] patients), maculopapular rash (seven [8%] patients), and fatigue (six [7%] patients). Treatment-related serious adverse events occurred in 15 (17%) patients. Three (3%) patients died due to acute kidney injury, metabolic acidosis, and multiple organ dysfunction syndrome (one [1%] each) within 30 days of first dose and these deaths were considered by the investigator to be related to treatment; a fourth death from pneumonitis occurred more than 30 days after the last dose and was also considered to be related to treatment. Interpretation: Treatment with enfortumab vedotin was tolerable and confirmed responses were seen in 52% of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma who were previously treated with PD-1 or PD-L1 inhibitors. These patients have few treatment options, and enfortumab vedotin could be a promising new therapy for a patient population with a high unmet need. Funding: Astellas Pharma Global Development and Seagen.
MeSH term(s)	Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/genetics ; Carcinoma/drug therapy ; Carcinoma/genetics ; Carcinoma/pathology ; Cell Adhesion Molecules/genetics ; Cisplatin/adverse effects ; Disease-Free Survival ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/genetics ; Response Evaluation Criteria in Solid Tumors ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/genetics ; Urologic Neoplasms/pathology ; Urothelium/drug effects ; Urothelium/pathology
Chemical Substances	Antibodies, Monoclonal ; B7-H1 Antigen ; CD274 protein, human ; Cell Adhesion Molecules ; Immune Checkpoint Inhibitors ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; NECTIN4 protein, human ; enfortumab vedotin (DLE8519RWM) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2021-05-12
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(21)00094-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7).

Trowbridge, Janet M / Rudisill, Jennifer A / Ron, Dina / Gallo, Richard L

The Journal of biological chemistry

2002 Volume 277, Issue 45, Page(s) 42815–42820

Abstract: FGF-7 is induced after injury and induces the proliferation of keratinocytes. Like most members of the FGF family, the activity of FGF-7 is strongly influenced by binding to heparin, but this glycosaminoglycan is absent on keratinocyte cell surfaces and ... ...

Abstract	FGF-7 is induced after injury and induces the proliferation of keratinocytes. Like most members of the FGF family, the activity of FGF-7 is strongly influenced by binding to heparin, but this glycosaminoglycan is absent on keratinocyte cell surfaces and minimally present in the wound environment. In this investigation we compared the relative activity of heparan sulfate and chondroitin sulfate B (dermatan sulfate), glycosaminoglycans that are present in wounds. A lymphoid cell line (BaF/KGFR) containing the FGF-7 receptor (FGFR2 IIIb) was treated with FGF-7 and with various glycosaminoglycans. FGF-7 did not support cell proliferation in the absence of glycosaminoglycan or with addition of heparan sulfate or chondroitin sulfate A/C but did stimulate BaF/KGFR division in the presence of dermatan sulfate or highly sulfated low molecular weight fractions of dermatan. Dermatan sulfate also enabled FGF-7-dependent phosphorylation of mitogen-activated protein kinase and promoted binding of radiolabeled FGF-7 to FGFR2 IIIb. In addition, dermatan sulfate and FGF-7 stimulated growth of normal keratinocytes in culture. Thus, dermatan sulfate, the predominant glycosaminoglycan in skin, is the principle cofactor for FGF-7.
MeSH term(s)	Animals ; Cell Division/drug effects ; Cell Line ; Cells, Cultured ; Dermatan Sulfate/pharmacology ; Fibroblast Growth Factor 1/pharmacology ; Fibroblast Growth Factor 7 ; Fibroblast Growth Factors/pharmacology ; Fibroblast Growth Factors/physiology ; Glycosaminoglycans/isolation & purification ; Glycosaminoglycans/pharmacology ; Humans ; Intestinal Mucosa/chemistry ; Keratinocytes/drug effects ; Keratinocytes/physiology ; Kinetics ; Lymphocytes ; Mice ; Recombinant Proteins/pharmacology ; Swine ; Transfection
Chemical Substances	FGF7 protein, human ; Fgf7 protein, mouse ; Glycosaminoglycans ; Recombinant Proteins ; Fibroblast Growth Factor 1 (104781-85-3) ; Fibroblast Growth Factor 7 (126469-10-1) ; Dermatan Sulfate (24967-94-0) ; Fibroblast Growth Factors (62031-54-3)
Language	English
Publishing date	2002-09-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	2997-x
ISSN	1083-351X ; 0021-9258
ISSN (online)	1083-351X
ISSN	0021-9258
DOI	10.1074/jbc.M204959200
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Dermatan sulfate proteoglycan and glycosaminoglycan synthesis is induced in fibroblasts by transfer to a three-dimensional extracellular environment.

Lee, Phillip H A / Trowbridge, Janet M / Taylor, Kristen R / Morhenn, Vera B / Gallo, Richard L

The Journal of biological chemistry

2004 Volume 279, Issue 47, Page(s) 48640–48646

Abstract: Composition and architecture of the extracellular matrix dictate cell behavior. Proteoglycans bind multiple components of the extracellular matrix by serving as important regulators of cell behavior. Given the influence of culture architecture on cell ... ...

Abstract	Composition and architecture of the extracellular matrix dictate cell behavior. Proteoglycans bind multiple components of the extracellular matrix by serving as important regulators of cell behavior. Given the influence of culture architecture on cell function, we investigated whether switching NIH3T3 fibroblasts from growth on type 1 collagen in monolayer to a collagen gel might influence dermatan sulfate expression. Immunofluorescent staining, immunoblot, and Western blot demonstrated an induction in decorin expression in cells switched to collagen gels. This induction was associated with a 40-fold increase in decorin transcript expression determined by quantitative real time PCR. Disaccharide analysis of extracted glycosaminoglycans from collagen gels showed an increase in total glycosaminoglycan and in the ratio of chondroitin sulfate to heparan sulfate compared with monolayer culture. The ratio of chondroitin sulfate to heparan sulfate likewise increased on syndecan-1 from gel culture. Digestion with chondroitinase B showed that this induced chondroitin sulfate was dermatan sulfate. Syndecan-1 extracted from wounded mouse skin also displayed an increase in dermatan sulfate synthesis compared with unwounded skin. Furthermore, glycosaminoglycans from collagen gel culture activated keratinocyte growth factor, whereas glycosaminoglycans from monolayer culture lacked this ability. These findings suggest that regulation of dermatan sulfate and dermatan sulfate proteoglycan is dependent on extracellular matrix architecture. The ability of collagen gel culture to mimic better the in vivo dermal environment may be due in part to this influence on dermatan sulfate and dermatan sulfate proteoglycan synthesis.
MeSH term(s)	Animals ; Blotting, Western ; Cell Culture Techniques/methods ; Cell Proliferation ; Chondroitin Sulfate Proteoglycans/chemistry ; Chondroitin Sulfates/chemistry ; Chondroitinases and Chondroitin Lyases/chemistry ; Chromatography, Ion Exchange ; Collagen/chemistry ; DNA/chemistry ; Decorin ; Dermatan Sulfate/chemistry ; Disaccharides/chemistry ; Dose-Response Relationship, Drug ; Extracellular Matrix/metabolism ; Extracellular Matrix Proteins ; Fibroblasts/metabolism ; Glycosaminoglycans/chemistry ; Immunoblotting ; Keratinocytes/metabolism ; Kinetics ; Membrane Glycoproteins/chemistry ; Mice ; Mice, Inbred BALB C ; Microscopy, Fluorescence ; NIH 3T3 Cells ; Nitrous Acid/chemistry ; Proteoglycans/biosynthesis ; Proteoglycans/chemistry ; Receptor Protein-Tyrosine Kinases/chemistry ; Receptor, Fibroblast Growth Factor, Type 2 ; Receptors, Fibroblast Growth Factor/chemistry ; Reverse Transcriptase Polymerase Chain Reaction ; Skin/metabolism ; Syndecan-1 ; Syndecans ; Time Factors ; Wound Healing
Chemical Substances	Chondroitin Sulfate Proteoglycans ; Dcn protein, mouse ; Decorin ; Disaccharides ; Extracellular Matrix Proteins ; Glycosaminoglycans ; Membrane Glycoproteins ; Proteoglycans ; Receptors, Fibroblast Growth Factor ; Sdc1 protein, mouse ; Syndecan-1 ; Syndecans ; dermatan sulfate proteoglycan ; Dermatan Sulfate (24967-94-0) ; Chondroitin Sulfates (9007-28-7) ; Collagen (9007-34-5) ; DNA (9007-49-2) ; Fgfr2 protein, mouse (EC 2.7.10.1) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 2 (EC 2.7.10.1) ; Chondroitinases and Chondroitin Lyases (EC 4.2.2.-) ; chondroitinase B (EC 4.2.2.-) ; Nitrous Acid (T2I5UM75DN)
Language	English
Publishing date	2004-09-03
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	2997-x
ISSN	1083-351X ; 0021-9258
ISSN (online)	1083-351X
ISSN	0021-9258
DOI	10.1074/jbc.M407241200
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Hyaluronan fragments stimulate endothelial recognition of injury through TLR4.

Taylor, Kristen R / Trowbridge, Janet M / Rudisill, Jennifer A / Termeer, Christian C / Simon, Jan C / Gallo, Richard L

The Journal of biological chemistry

2004 Volume 279, Issue 17, Page(s) 17079–17084

Abstract: Tissues must quickly recognize injury to respond to the rapid pace of microbial growth. In skin, dermal microvascular endothelial cells must also react to danger signals from the surrounding tissue and immediately participate by initiating the wound ... ...

Abstract	Tissues must quickly recognize injury to respond to the rapid pace of microbial growth. In skin, dermal microvascular endothelial cells must also react to danger signals from the surrounding tissue and immediately participate by initiating the wound repair process. Components of the extracellular matrix such as hyaluronan are rapidly broken down into smaller molecular weight oligosaccharides in a wound, and these can activate a variety of biological processes. This study set out to determine if hyaluronan fragments released following injury can stimulate endothelial cells and what mechanism is responsible for this response. Using genechip microarray analysis, a response to hyaluronan fragments was detected in endothelial cells with the most significant increase observed for the chemokine IL-8. This observation was verified with qualitative reverse transcriptase-PCR and ELISA in human endothelial cell culture, and in a mouse model by observing serum levels of MIP-2 and KC following hyaluronan fragment administration in vivo. Activation was TLR4-dependent, as shown by use of TLR4 blocking antibody and TLR4-deficient mice, but not due to the presence of undetected contaminants as shown by inactivation following digestion with the hyaluronan-degrading enzyme chondroitinase ABC or incubation with the hyaluronan-specific blocking peptide Pep-1. Inactivation of LPS activity failed to diminish the action of hyaluronan fragments. These observations suggest that endogenous components of the extracellular matrix can stimulate endothelia to trigger recognition of injury in the initial stages of the wound defense and repair response.
MeSH term(s)	Animals ; Cells, Cultured ; Chondroitin ABC Lyase/metabolism ; Dermis/cytology ; Dose-Response Relationship, Drug ; Endothelium, Vascular/metabolism ; Enzyme-Linked Immunosorbent Assay ; Extracellular Matrix/metabolism ; Humans ; Hyaluronic Acid/chemistry ; Hyaluronic Acid/pharmacology ; Interleukin-8/metabolism ; Lipopolysaccharides/pharmacology ; Membrane Glycoproteins/metabolism ; Membrane Glycoproteins/physiology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C3H ; Microcirculation ; Oligonucleotide Array Sequence Analysis ; Peptides/pharmacology ; Polymerase Chain Reaction ; Receptors, Cell Surface/metabolism ; Receptors, Cell Surface/physiology ; Reverse Transcriptase Polymerase Chain Reaction ; Time Factors ; Toll-Like Receptor 4 ; Toll-Like Receptors ; Wound Healing
Chemical Substances	Interleukin-8 ; Lipopolysaccharides ; Membrane Glycoproteins ; Peptides ; Receptors, Cell Surface ; TLR4 protein, human ; Toll-Like Receptor 4 ; Toll-Like Receptors ; Hyaluronic Acid (9004-61-9) ; Chondroitin ABC Lyase (EC 4.2.2.20)
Language	English
Publishing date	2004-02-05
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	2997-x
ISSN	1083-351X ; 0021-9258
ISSN (online)	1083-351X
ISSN	0021-9258
DOI	10.1074/jbc.M310859200
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Stress, salt flux, and dynamics of a partially mixed estuary

Fredericks, Janet J. / Trowbridge, John H. / Geyer, W. Rockwell / Williams, Albert J. / Bowen, Melissa M. / Woodruff, Jonathan D.

Abstract: Funding was provided by the National Science Foundationunder Grant OCE-94-15617 and The Hudson River Foundation. ...

Abstract	Funding was provided by the National Science Foundationunder Grant OCE-94-15617 and The Hudson River Foundation.
Language	en_us
Document type	Article
Database	AGRIS - International Information System for the Agricultural Sciences and Technology

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Turbulence in the shallow nearshore environment during SANDYDUCK '97

Fredericks, Janet J. / Trowbridge, John H. / Voulgaris, George

Abstract: ... from late August through late November of 1997 at a water depth of approximately 4.5 m off Duck ...

Abstract	An array of five acoustic Doppler velocimeters(ADV), which produce high quality measurements of the three-dimensional velocity vector in a sample volume with a scale of one centimeter, was deployed from late August through late November of 1997 at a water depth of approximately 4.5 m off Duck, North Carolina. The sensors were deployed near the sea floor but above the centimeters-thick wave boundary layer, and the sampling scheme was designed to resolve turbulence statistics averaged over tens of minutes, much longer than typical wave periods but shorter than time scales associated with variablity of energetic wind-driven and wave-driven alongshore flows.
Language	en_us
Document type	Article
Database	AGRIS - International Information System for the Agricultural Sciences and Technology

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED